138 related articles for article (PubMed ID: 30225958)
1. Characterising the Subsite Specificity of Urokinase-Type Plasminogen Activator and Tissue-Type Plasminogen Activator using a Sequence-Defined Peptide Aldehyde Library.
Li CY; de Veer SJ; Law RHP; Whisstock JC; Craik DJ; Swedberg JE
Chembiochem; 2019 Jan; 20(1):46-50. PubMed ID: 30225958
[TBL] [Abstract][Full Text] [Related]
2. Molecular basis of specific inhibition of urokinase plasminogen activator by amiloride.
Jankun J; Skrzypczak-Jankun E
Cancer Biochem Biophys; 1999 Jul; 17(1-2):109-23. PubMed ID: 10738907
[TBL] [Abstract][Full Text] [Related]
3. A urokinase-type plasminogen activator-inhibiting cyclic peptide with an unusual P2 residue and an extended protease binding surface demonstrates new modalities for enzyme inhibition.
Hansen M; Wind T; Blouse GE; Christensen A; Petersen HH; Kjelgaard S; Mathiasen L; Holtet TL; Andreasen PA
J Biol Chem; 2005 Nov; 280(46):38424-37. PubMed ID: 16141208
[TBL] [Abstract][Full Text] [Related]
4. Evidence for the regulation of urokinase and tissue type plasminogen activators by the serpin, protein C inhibitor, in semen and blood plasma.
España F; Estellés A; Fernández PJ; Gilabert J; Sánchez-Cuenca J; Griffin JH
Thromb Haemost; 1993 Dec; 70(6):989-94. PubMed ID: 8165623
[TBL] [Abstract][Full Text] [Related]
5. Structural basis for selectivity of a small molecule, S1-binding, submicromolar inhibitor of urokinase-type plasminogen activator.
Katz BA; Mackman R; Luong C; Radika K; Martelli A; Sprengeler PA; Wang J; Chan H; Wong L
Chem Biol; 2000 Apr; 7(4):299-312. PubMed ID: 10779411
[TBL] [Abstract][Full Text] [Related]
6. A cyclic peptidylic inhibitor of murine urokinase-type plasminogen activator: changing species specificity by substitution of a single residue.
Andersen LM; Wind T; Hansen HD; Andreasen PA
Biochem J; 2008 Jun; 412(3):447-57. PubMed ID: 18318660
[TBL] [Abstract][Full Text] [Related]
7. The surface of prostate carcinoma DU145 cells mediates the inhibition of urokinase-type plasminogen activator by maspin.
McGowen R; Biliran H; Sager R; Sheng S
Cancer Res; 2000 Sep; 60(17):4771-8. PubMed ID: 10987285
[TBL] [Abstract][Full Text] [Related]
8. Engineering inhibitors highly selective for the S1 sites of Ser190 trypsin-like serine protease drug targets.
Katz BA; Sprengeler PA; Luong C; Verner E; Elrod K; Kirtley M; Janc J; Spencer JR; Breitenbucher JG; Hui H; McGee D; Allen D; Martelli A; Mackman RL
Chem Biol; 2001 Nov; 8(11):1107-21. PubMed ID: 11731301
[TBL] [Abstract][Full Text] [Related]
9. Pro-urokinase-type plasminogen activator is a substrate for hepsin.
Moran P; Li W; Fan B; Vij R; Eigenbrot C; Kirchhofer D
J Biol Chem; 2006 Oct; 281(41):30439-46. PubMed ID: 16908524
[TBL] [Abstract][Full Text] [Related]
10. Identification of tissue-type plasminogen activator-specific plasminogen activator inhibitor-1 mutants. Evidence that second sites of interaction contribute to target specificity.
Sherman PM; Lawrence DA; Verhamme IM; Paielli D; Shore JD; Ginsburg D
J Biol Chem; 1995 Apr; 270(16):9301-6. PubMed ID: 7721851
[TBL] [Abstract][Full Text] [Related]
11. A peptide mimicking the C-terminal part of the reactive center loop induces the transition to the latent form of plasminogen activator inhibitor type-1.
D'Amico S; Martial JA; Struman I
FEBS Lett; 2012 Mar; 586(6):686-92. PubMed ID: 22449964
[TBL] [Abstract][Full Text] [Related]
12. Plasminogen activators augment endothelial cell organization in vitro by two distinct pathways.
Schnaper HW; Barnathan ES; Mazar A; Maheshwari S; Ellis S; Cortez SL; Baricos WH; Kleinman HK
J Cell Physiol; 1995 Oct; 165(1):107-18. PubMed ID: 7559792
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of urokinase by 4-substituted benzo[b]thiophene-2-carboxamidines: an important new class of selective synthetic urokinase inhibitor.
Towle MJ; Lee A; Maduakor EC; Schwartz CE; Bridges AJ; Littlefield BA
Cancer Res; 1993 Jun; 53(11):2553-9. PubMed ID: 8495419
[TBL] [Abstract][Full Text] [Related]
14. Discovery and SAR of Novel and Selective Inhibitors of Urokinase Plasminogen Activator (uPA) with an Imidazo[1,2-a]pyridine Scaffold.
Gladysz R; Adriaenssens Y; De Winter H; Joossens J; Lambeir AM; Augustyns K; Van der Veken P
J Med Chem; 2015 Dec; 58(23):9238-57. PubMed ID: 26575094
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of plasminogen activators attenuates the death of differentiated retinal ganglion cells and stabilizes their neurite network in vitro.
Harvey R; Chintala SK
Invest Ophthalmol Vis Sci; 2007 Apr; 48(4):1884-91. PubMed ID: 17389524
[TBL] [Abstract][Full Text] [Related]
16. Plasma tissue-type plasminogen activator increases fibrinolytic activity of exogenous urokinase-type plasminogen activator.
Shenkman B; Livnat T; Budnik I; Tamarin I; Einav Y; Martinowitz U
Blood Coagul Fibrinolysis; 2012 Dec; 23(8):729-33. PubMed ID: 22918041
[TBL] [Abstract][Full Text] [Related]
17. Regulation and interactions in the activation of cell-associated plasminogen.
Myöhänen H; Vaheri A
Cell Mol Life Sci; 2004 Nov; 61(22):2840-58. PubMed ID: 15558213
[TBL] [Abstract][Full Text] [Related]
18. Biological mechanisms underlying the clinical effects of RU 486: modulation of cultured endometrial stromal cell plasminogen activator and plasminogen activator inhibitor expression.
Lockwood CJ; Krikun G; Papp C; Aigner S; Schatz F
J Clin Endocrinol Metab; 1995 Apr; 80(4):1100-5. PubMed ID: 7714076
[TBL] [Abstract][Full Text] [Related]
19. Distinguishing the specificities of closely related proteases. Role of P3 in substrate and inhibitor discrimination between tissue-type plasminogen activator and urokinase.
Ke SH; Coombs GS; Tachias K; Navre M; Corey DR; Madison EL
J Biol Chem; 1997 Jun; 272(26):16603-9. PubMed ID: 9195973
[TBL] [Abstract][Full Text] [Related]
20. Identification of a novel inhibitor of urokinase-type plasminogen activator.
Zhu M; Gokhale VM; Szabo L; Munoz RM; Baek H; Bashyam S; Hurley LH; Von Hoff DD; Han H
Mol Cancer Ther; 2007 Apr; 6(4):1348-56. PubMed ID: 17431113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
